|
|
Vaccine Detail
|
live attenuated Brucella abortus Flu-BA influenza vector vaccine |
| Vaccine Information |
- Vaccine Name: live attenuated Brucella abortus Flu-BA influenza vector vaccine
- Target Pathogen: Brucella spp.
- Target Disease: Brucellosis
- Vaccine Ontology ID: VO_0009371
- Type: Live attenuated vaccine + Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Sheep
- Antigen: Omp16; L7/L12
-
Adjuvant:
Montanide Gel01
- Preparation: Influenza viral vector based Brucella abortus vaccine administered with Montanide Gel01 adjuvant. (Tabynov et al, 2016b)
- Description: Previously developed and evaluated in cattle; this study aimed to establish proof-of-concept efficacy in sheep and goats. Efficacy: Complete protection in 57.1% of sheep and 42.9% of goats against B. melitensis 16M challenge; significantly lower infection index and tissue colonization compared to negative controls. Immune response: No antibody response against Brucella Omp16 and L7/L12 proteins detected up to 56 days post-initial vaccination; significant antigen-specific T cell response indicated by increased lymphocyte stimulation index and enhanced IFN-γ secretion at day 56 post-vaccination. (Tabynov et al, 2016b)
|
| Host Response |
|
|
| References |
Tabynov et al, 2016b: Tabynov K, Yespembetov B, Matikhan N, Ryskeldinova S, Zinina N, Kydyrbayev Z, Assanzhanova N, Tabynov K, Renukaradhya GJ, Mukhitdinova G, Sansyzbay A. First evaluation of an influenza viral vector based Brucella abortus vaccine in sheep and goats: Assessment of safety, immunogenicity and protective efficacy against Brucella melitensis infection. Veterinary microbiology. 2016 Dec 25; 197; 15-20. [PubMed: 27938677].
|
|
